The Role of the Immune and Inflammatory Systems in Hypertension

• Conditions: Vascular Diseases; Hypertension; Inflammation
• Interventions: Other: None involved

• Registration Number: NCT04015635
• Lead Sponsor: University of Glasgow

Brief Summary

To define the cytokine and cellular immune signature of primary hypertension. Cross sectional clinical/laboratory study.

Detailed Description

Experimental data show the presence of immune and inflammatory systems dysregulation in hypertension. Understanding of the inflammatory and immune nature of hypertension is currently based on studies in rodent models of hypertension, but is supported by human epidemiological and genome wide association studies (GWAS) studies. It is now essential to identify key checkpoints and inflammatory mechanism(s) involved in human hypertension in comprehensive and sufficiently powered studies, which will then be able to guide subsequent in-depth hypothesis-driven mechanistic studies. This approach may provide the basis for future randomized clinical trials (RCTs).

To define the relationships and predictive value of the immune signature of hypertension and clinical phenotypes of hypertension :

* Predictive value of immune signature for blood pressure parameters measured by ambulatory blood pressure measurements (ABPM)

* Predictive value of immune signature for endothelial function assessed by Endo-PAT2000 and flow mediated dilatation (FMD) both complementary non-invasive techniques.

* Predictive value of immune signature for vascular stiffness and central pressure assessed by SphygmoCor

* Predictive value of immune signature for renal function parameters

* Predictive value of immune signature for cognitive function. To define genetic determinants of immune signature of hypertension.

Study Timeline

• Study First Submitted: 2019-04-30
• Study Start: 2019-05-07
• Study First Submitted QC: 2019-07-08
• Study First Posted: 2019-07-11
• Status Verified: 2021-05
• Last Update Submitted: 2021-05-12
• Last Update Posted: 2021-05-14
• Primary Completion: 2021-09-01
• Study Completion: 2021-09-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

• Age between 18-55 years
• Cases: Office blood pressure ≥140 and ≥90
• Controls: Office blood pressure <140 and <90 and age, sex and BMI matching to cases

Exclusion Criteria

• Age >55 years old;
• Secondary hypertension (including e.g. adrenal tumours, pheochromocytoma, renal artery stenosis; thyroid disease)
• Acute inflammatory disorders incl. flu, rhinitis, sinusitis etc. within 3 weeks;
• hospitalization within the past 3 months;
• Life expectancy of < 3 years;
• History of alcohol/substance abuse
• Inflammatory conditions e.g. Allergic disorders; chronic infections, COPD, tuberculosis; hepatitis B or C; pneumonitis, bronchiectasis; pericardial or pleural effusion, ascites; liver disease;
• Chronic inflammatory/autoimmune conditions such (e.g. SLE, rheumatoid arthritis, ulcerative colitis/Crohn's disease; non-basal cell malignancy or myelo- or lymphoproliferative disease within the past 5 years; known HIV+; Immunizations (3 months); pulmonary hypertension;
• Pregnancy, nursing;
• History of symptomatic coronary artery disease (events) or heart failure;
• BMI>40,
• diabetes/glucose intolerance (fasting glucose, HbA1; testing, glucose challenge where indicated);
• Known albuminuria/microalbuminuria;
• GFR<60mL/min/1.73m2.
• Any chronic concurrent treatment: Use of systemic or local steroids/immunosuppressive agents (within 6 months) of the inclusion; Current (within past 3 months) use of anti-hypertensive medication;
• Major depressive illness or other psychiatric conditions.
• Participants who decline participation in the study or who are unable to provide informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Control	None involved	80 WITHOUT hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring. Clinical and laboratory assessment. NO intervention.
Study group	None involved	80 with hypertension, defined on office BP readings and confirmed with ambulatory blood pressure monitoring. Clinical and laboratory assessment. NO intervention.

Primary Outcome Measures

Name	Time	Method
demographics: BMI	rolling analysis until total number recruited or end of study period (June 2021)	in kg/m\^2; calculated from height in meters and weight in kg
cellular immune signature of primary hypertension: flow cytometry quantification of peripheral blood monocyte subtypes	rolling analysis until total number recruited or end of study period (June 2021)	measuring expression of B cells markers, T cell markers, and DC cell markers
demographics: blood pressure	rolling analysis until total number recruited or end of study period (June 2021)	systolic and diastolic; office and ambulatory; in mmHG

Secondary Outcome Measures

Name	Time	Method
carotid intimal media thickness (mm)	until total number recruited or end of study period (June 2021)	measure of vascular stiffness and central pressure
assessed by SphygmoCor (meters/second)	until total number recruited or end of study period (June 2021)	measure of vascular stiffness and central pressure
flow mediated dilatation (FMD) (percent)	until total number recruited or end of study period (June 2021)	as a measure of endothelial function
Interheart Diet Questionnaire score	until end of study period (June 2021)	Questionnaire measures of health and activity. Based on known risk factors ie smoking diabetes, family history, dietary factors. Used as a validated measure of cardiovascular risk; score from 0 (minimal risk) to 48 (high risk)
Endo-PAT2000 "hyperaemia index"	until total number recruited or end of study period (June 2021)	As a measure of endothelial function: measuring Peripheral Arterial Tone (PAT) signal changes to a reactive hyperemia challenge. The PAT signal is a measure of the digital pulsatile volume. The expected response is of a post occlusion increase of the PAT signal amplitude. PAT score is provided automatically by the system's software and is basically the ratio between the post- to pre- occlusion average signal size, corrected for systemic changes and baseline level.; changes
serum Creatinine (mMol/L)	until total number recruited or end of study period (June 2021)	measure of renal function
"International Physical Activity Questionnaire" (score)	until end of study period (June 2021)	Questionnaire measures of physical activity. From hours of sedentary time, mild/moderate/vigorous activity over a week, it then calculates METs/week.

Trial Locations

Locations (1)

Clinical Research Facility; 🇬🇧 Glasgow, City Of Glasgow, United Kingdom